/

DYN

Dyne Therapeutics, Inc.Open

15.76−0.20 −1.25%USD

NasdaqGS · as of Oct 13, 10:18 ET · 15m delay

Open

15.97

Prev close

15.96

Day range

15.6315.99

52-week range

13.8827.31

Volume

321.52K0.11×

Mkt cap

2.94B

P/E ttm

—

Fwd P/E

-4.73

EPS ttm

-3.30

Div yield

0.00%

Earnings

—

From 52w high

−42.28%

Price Chart

Yahoo Finance · delayed

DYNOct 13, 2026O 15.97H 15.99L 15.63C 15.76−0.20 (−1.25%)Vol 321.52K

SMA 5021.21
SMA 20019.48

1Y change +12.17% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DYN Dyne Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.34%
1 month: −13.45%
3 months: −33.73%
6 months: −20.44%
Year to date: −19.43%
1 year: +12.33%

Valuation & ownership

Market cap: 2.94B
Enterprise value: 2.32B
P/E (ttm): —
Forward P/E: -4.73
PEG ratio: —
Price / book: 3.72
Price / sales (ttm): —
EV / EBITDA: -4.33
EPS (ttm): -3.30
EPS (forward): -3.34
Beta (5y monthly): 1.12
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 186.75M
Float: 186.23M
Short % of float: 17.79%
Short ratio (days): 7.25
Held by insiders: 0.24%
Held by institutions: 103.68%
Avg volume (3m): 2.90M
50-day average: 21.40
200-day average: 19.50
52-week change: +12.33%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 32.8
vs 50-day SMA: −25.68%
vs 200-day SMA: −19.09%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.84%
Realised vol (20d, ann.): 46.0%
From 52-week high: −42.28%
From 52-week low: +13.54%

ANR

Analyst Consensus

15 analysts

Consensus

Strong buy

1.35 on a 1 (strong buy) – 5 (sell) scale

Mean target

35.73

+126.73% implied

Low 10.00Median 37.00High 50.00

Recommendation trend

Now16 / 0 / 1
1m ago / 1 /

DES

About Dyne Therapeutics, Inc.

Yahoo Finance profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 289
Headquarters: Waltham, MA, United States
Website: dyne-tx.com
Officers: Mr. John G. Cox M.B.A. CEO, President & Director
Mr. Erick J. Lucera C.F.A., CPA CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer
Dr. Oxana Beskrovnaya Ph.D. Chief Innovation Officer
Ms. Johanna Friedl-Naderer Chief Commercial Officer

SEAS

Seasonality · DYN

2020–2026 · monthly returns

Strongest month Jul +14.38%Weakest month Mar −6.32%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.5	-12.7	16.1	-3.2	10.1	14.9	13.4	1.0	-36.6	-2.2			−19.4%
2025	-39.6	-4.3	-23.1	12.7	1.4	-20.4	3.5	37.0	-6.2	78.5	-3.0	-10.7	−17.0%
2024	60.9	25.7	5.5	-10.8	26.0	10.7	21.6	7.4	-22.1	-19.7	6.1	-23.0	+77.1%
2023	26.0	-11.8	-10.6	-10.1	25.8	-13.7	8.3	-6.4	-21.4	-21.3	57.2	20.0	+14.8%
2022	-37.6	15.5	12.5	-17.2	-39.7	42.8	52.7	-6.6	29.6	-10.2	2.6	-0.9	−2.5%
2021	-8.0	-4.4	-15.9	26.7	-2.9	10.1	-14.1	-6.3	-4.1	-10.7	-2.1	-16.3	−43.4%
2020										2.4	-2.5	4.2	+4.0%

INSD

Insider Activity · DYN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

65.1K shares

Sells, 6 months

6.78M shares

Net shares

−6.72M

Net change in insider shares

−93.80%

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Posner Brian S.Director	Purchase at price 16.00 per share.	2.5K	$40.00K
Sep 7, 2026	Cox JohnChief Executive Officer	Sale at price 18.88 per share.	5.7K	$106.82K
Sep 7, 2026	Friedl-Naderer JohannaOfficer	Sale at price 24.28 - 24.35 per share.	1.1K	$26.41K
Sep 7, 2026	Kerr DouglasOfficer	Sale at price 18.88 - 24.35 per share.	5K	$115.55K
Aug 13, 2026	Rhodes Jason PDirector	Sale at price 25.00 - 26.20 per share.	2.59M	$65.18M
Aug 12, 2026	Cox JohnChief Executive Officer	Sale at price 26.28 per share.	5K	$131.03K
Aug 12, 2026	Friedl-Naderer JohannaOfficer	Sale at price 26.28 per share.	226	$5.94K
Aug 12, 2026	Lucera Erick J.Chief Financial Officer	Sale at price 26.28 per share.	1.8K	$47.23K
Aug 12, 2026	Kerr DouglasOfficer	Sale at price 26.28 per share.	1.6K	$40.89K
Jul 26, 2026	Kersten DirkDirector	Sale at price 25.50 - 26.04 per share.	261.5K	$6.67M
Jul 6, 2026	Rhodes Jason PDirector	Sale at price 22.79 - 23.62 per share.	777.5K	$17.86M
Jun 28, 2026	Rhodes Jason PDirector	Sale at price 21.14 - 21.28 per share.	504.7K	$10.71M
Jun 24, 2026	Rhodes Jason PDirector	Sale at price 21.02 - 21.13 per share.	267.8K	$5.65M
Jun 24, 2026	Lucera Erick J.Chief Financial Officer	Sale at price 20.37 per share.	2.4K	$48.11K
Jun 22, 2026	Kersten DirkDirector	Sale at price 20.57 - 21.47 per share.	264K	$5.46M
Jun 17, 2026	Kersten DirkDirector	Sale at price 20.07 - 20.14 per share.	84.4K	$1.70M
Jun 15, 2026	Cox JohnChief Executive Officer	Sale at price 18.33 per share.	2.7K	$49.18K
Jun 15, 2026	Friedl-Naderer JohannaOfficer	Sale at price 18.33 per share.	145	$2.66K
Jun 15, 2026	Kerr DouglasOfficer	Sale at price 18.33 per share.	887	$16.26K
Jun 7, 2026	Posner Brian S.Director	Purchase at price 16.94 per share.	2K	$33.88K

13F

Investors Holding DYN

latest 13F filings of 29 followed managers

Investors holding DYN
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.0M	0.01%	360.57K	−32%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

DYN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DYN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Dyne Therapeutics, Inc.

Seasonality · DYN

Insider Activity · DYN

Congress Trades · DYN

Investors Holding DYN

Investors Holding DYN

Congress Trades · DYN

Insider Activity · DYN

Seasonality · DYN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Dyne Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News